While the TriNetX database allows for the analysis of large T2D cohorts treated with GLP-1 RAs in clinical settings, it may not capture intraclass and interclass differences between medications and prescribing patterns
They work with the bodys natural processes rather than forcing things along, making them a good option for long-term constipation management on GLP-1
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
& Yawuz, M
Garetosmab, activin A inhibitor antibody for muscle-preservation combination regimens in obesity Recent Highlights: In June 2026, the company announced it would present new clinical data from the Phase 2 COURAGE trial that examines the effects of trevogrumab (anti-GDF8) on lean mass in people with obesity treated with semaglutide
Available exclusively at Revital Trichology & Wellness, Mumbai Book your consultation today and begin your personalized peptide therapy journey in India.
